Investors Alert: Pomerantz Law Firm Probes Tandem Diabetes Care, Inc. Claims
On October 3, 2025, Pomerantz LLP announced it is investigating claims on behalf of investors in Tandem Diabetes Care, Inc. (NASDAQ: TNDM). This investigation centers on allegations of securities fraud and possible unlawful business practices involving certain officers and directors of the company. Investors are urged to reach out for more information on joining the class action.
The scrutiny comes in light of recent disclosures made public on August 7, 2025, where Tandem revealed significant issues with its insulin pumps. Specifically, a malfunction was identified which posed serious risks to users. The company indicated that this malfunction could result in a failure to deliver insulin, potentially leading to hyperglycemia—a condition marked by dangerously high blood sugar levels that can result in hospitalization or require immediate medical intervention.
Following the announcement of these complications, Tandem’s stock price experienced a dramatic decline, plummeting $2.87, equivalent to a 19.94% drop, closing at $11.52 per share that same day. This considerable drop has heightened concerns among investors regarding the stability and reliability of the company's operations and products.
Pomerantz LLP, with a legacy of over 85 years in the domain of securities class litigation, is recognized as a leading firm in this field. Founded by the esteemed Abraham L. Pomerantz, the firm has garnered a reputation for championing the rights of those affected by securities fraud and corporate mismanagement. Throughout its history, the firm has secured numerous multimillion-dollar settlements for class members, demonstrating a strong commitment to pursuing justice for investors.
The investigation by Pomerantz may open avenues for compensation for those who have suffered losses due to the reported issues surrounding Tandem Diabetes Care's insulin delivery systems. As such investigations unfold, transparency and accountability are crucial components that both the firm and affected investors will be seeking in their pursuit of adequate redress and prevention of future incidents.
Anyone who believes they might be impacted by these developments is encouraged to reach out to Danielle Peyton via email or by phone for further details and guidance on how to proceed. Investors should maintain a close watch on any further announcements from Tandem, as the situation evolves, highlighting the critical importance of vigilance in the healthcare technology sector.
Contact Information:
For more details regarding the investigation or to express interest in joining the class action, individuals should contact Danielle Peyton at Pomerantz LLP via email at [email protected] or by calling 646-581-9980, extension 7980.
As stakeholders process this information, it underscores the vital responsibility of companies to ensure the safety and efficacy of their medical devices and the paramount importance of ethical conduct in business dealings, especially in fields that directly affect patient health and safety.
The scrutiny comes in light of recent disclosures made public on August 7, 2025, where Tandem revealed significant issues with its insulin pumps. Specifically, a malfunction was identified which posed serious risks to users. The company indicated that this malfunction could result in a failure to deliver insulin, potentially leading to hyperglycemia—a condition marked by dangerously high blood sugar levels that can result in hospitalization or require immediate medical intervention.
Following the announcement of these complications, Tandem’s stock price experienced a dramatic decline, plummeting $2.87, equivalent to a 19.94% drop, closing at $11.52 per share that same day. This considerable drop has heightened concerns among investors regarding the stability and reliability of the company's operations and products.
Pomerantz LLP, with a legacy of over 85 years in the domain of securities class litigation, is recognized as a leading firm in this field. Founded by the esteemed Abraham L. Pomerantz, the firm has garnered a reputation for championing the rights of those affected by securities fraud and corporate mismanagement. Throughout its history, the firm has secured numerous multimillion-dollar settlements for class members, demonstrating a strong commitment to pursuing justice for investors.
The investigation by Pomerantz may open avenues for compensation for those who have suffered losses due to the reported issues surrounding Tandem Diabetes Care's insulin delivery systems. As such investigations unfold, transparency and accountability are crucial components that both the firm and affected investors will be seeking in their pursuit of adequate redress and prevention of future incidents.
Anyone who believes they might be impacted by these developments is encouraged to reach out to Danielle Peyton via email or by phone for further details and guidance on how to proceed. Investors should maintain a close watch on any further announcements from Tandem, as the situation evolves, highlighting the critical importance of vigilance in the healthcare technology sector.
Contact Information:
For more details regarding the investigation or to express interest in joining the class action, individuals should contact Danielle Peyton at Pomerantz LLP via email at [email protected] or by calling 646-581-9980, extension 7980.
As stakeholders process this information, it underscores the vital responsibility of companies to ensure the safety and efficacy of their medical devices and the paramount importance of ethical conduct in business dealings, especially in fields that directly affect patient health and safety.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.